Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Infections Post Transplant

Valacyclovir for the prevention of cytomegalovirus infection after allogeneic stem cell transplantation: a single institution retrospective cohort analysis

Bone Marrow Transplantation volume 28, pages 265–270 (2001)Cite this article

Abstract

A retrospective single center study was performed to evaluate the safety and efficacy of valacyclovir for prevention of cytomegalovirus (CMV) infection (reactivation) after allogeneic stem cell transplantation (SCT). We compared a group of 31 patients at risk for CMV reactivation (donor, recipient or both seropositive for CMV) who received valacyclovir at an oral dose of 1 g three times a day for CMV prophylaxis with a matched cohort of 31 patients who did not receive the drug or any other form of CMV prophylaxis. Valacyclovir was used as primary prophylaxis in 12 patients and as secondary prophylaxis (after a prior CMV reactivation was effectively treated with either ganciclovir or foscarnet and without CMV antigenemia at the start of valacyclovir) in the remaining 19 patients. The two treatment groups were well matched for the donor–recipient CMV serological status and other pre-transplant characteristics. CMV reactivation was detected by blood antigenemia testing using a commercially available immunofluorescence assay for CMV lower matrix protein pp65 in circulating leukocytes. For primary prophylaxis, 3/12 patients who received valacyclovir reactivated CMV compared to 24/31 patients in the control group (P < 0.001). For secondary prophylaxis, 5/19 valacyclovir patients reactivated compared to 16/24 control patients (P < 0.05). Valacyclovir was well tolerated except for infrequent and mild gastrointestinal side-effects. There was no difference in the incidence of CMV disease in the two groups. Prophylaxis with valacyclovir appears to be safe and efficacious in preventing both primary and secondary CMV reactivation in at-risk patients after allogeneic SCT. Larger prospective randomized studies will be required to confirm these observations. Bone Marrow Transplantation (2001) 28, 265–270.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Wingard JR . Infections in allogeneic bone marrow transplant recipients Semin Oncol 1993 20: 80–87

    CAS  PubMed  Google Scholar 

  2. Winston DJ, Ho WG, Champlin RE . Cytomegalovirus infections after allogeneic bone marrow transplantation Rev Infect Dis 1990 12: S776–S792

    Article  PubMed  Google Scholar 

  3. Osarogiagbon RU, Defor TE, Weisdorf MA et al. CMV antigenemia following bone marrow transplantation: risk factors and outcomes Biol Blood Marrow Transplant 2000 6: 280–288

    Article  CAS  PubMed  Google Scholar 

  4. Humar A, Wood S, Lipton J et al. Effect of cytomegalovirus infection on 1-year mortality rates among recipients of allogeneic bone marrow transplants Clin Infect Dis 1998 26: 606–610

    Article  CAS  PubMed  Google Scholar 

  5. Maltezou H, Whimbey E, Abi-Said D et al. Cytomegalovirus disease in adult marrow transplant recipients receiving ganciclovir prophylaxis: a retrospective study Bone Marrow Transplant 1999 24: 665–669

    Article  CAS  PubMed  Google Scholar 

  6. Goodrich JM, Bowden RA, Fisher L et al. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant Ann Intern Med 1993 118: 173–178

    Article  CAS  PubMed  Google Scholar 

  7. Mori T, Okamoto S, Matsuoka S et al. Risk-adapted pre-emptive therapy for cytomegalovirus disease in patients undergoing allogeneic bone marrow transplantation Bone Marrow Transplant 2000 25: 765–769

    Article  CAS  PubMed  Google Scholar 

  8. Winston DJ, Ho WG, Bartoni K et al. Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients. Results of a placebo-controlled, double-blind trial Ann Intern Med 1993 118: 179–184

    Article  CAS  PubMed  Google Scholar 

  9. Bacigalupo A, Tedone E, Van Lint MT et al. CMV prophylaxis with foscarnet in allogeneic bone marrow transplant recipients at high risk of developing CMV infections Bone Marrow Transplant 1994 13: 783–788

    CAS  PubMed  Google Scholar 

  10. Prentice HG, Gluckman E, Powles RL et al. Long-term survival in allogeneic bone marrow transplant recipients following acyclovir prophylaxis for CMV infection. The European Acyclovir for CMV Prophylaxis Study Group Bone Marrow Transplant 1997 19: 129–133

    Article  CAS  PubMed  Google Scholar 

  11. Meyers JD, Reed EC, Shepp DH et al. Acyclovir for prevention of cytomegalovirus infection and disease after allogeneic marrow transplantation New Engl J Med 1988 318: 70–75

    Article  CAS  PubMed  Google Scholar 

  12. Boeckh M, Gooley TA, Bowden RA . Effect of high-dose acyclovir on survival in allogeneic marrow transplant recipients who received ganciclovir at engraftment or for cytomegalovirus pp65 antigenemia J Infect Dis 1998 178: 1153–1157

    Article  CAS  PubMed  Google Scholar 

  13. Weller S, Blum MR, Doucette M et al. Pharmacokinetics of the acyclovir pro-drug valaciclovir after escalating single- and multiple-dose administration to normal volunteers Clin Pharmacol Ther 1993 54: 595–605

    Article  CAS  PubMed  Google Scholar 

  14. Purifoy DJ, Beauchamp LM, de Miranda P et al. Review of research leading to new anti-herpesvirus agents in clinical development: valaciclovir hydrochloride (256U, the L-valyl ester of acyclovir) and 882C, a specific agent for varicella zoster virus J Med Virol 1993 (Suppl. 1) 139–145

    Article  Google Scholar 

  15. Soul-Lawton J, Seaber E, On N et al. Absolute bioavailability and metabolic disposition of valaciclovir, the L-valyl ester of acyclovir, following oral administration to humans Antimicrob Agents Chemother 1995 39: 2759–2764

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Lowance D, Neumayer HH, Legendre CM et al. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group New Engl J Med 1999 340: 1462–1470

    Article  CAS  PubMed  Google Scholar 

  17. Himmelmann-Jud B, Wuthrich RP, Weinreich T, Binswanger U . Successful use of oral valacyclovir in post-transplant cytomegalovirus infection in renal allograft recipients Nephrol Dial Transplant 1998 13: 1326–1327

    Article  CAS  PubMed  Google Scholar 

  18. Emery VC, Sabin C, Feinberg JE et al. Quantitative effects of valacyclovir on the replication of cytomegalovirus (CMV) in persons with advanced human immunodeficiency virus disease: baseline CMV load dictates time to disease and survival. The AIDS Clinical Trials Group 204/Glaxo Wellcome 123–014 International CMV Prophylaxis Study Group J Infect Dis 1999 180: 695–701

    Article  CAS  PubMed  Google Scholar 

  19. Feinberg JE, Hurwitz S, Cooper D et al. A randomized, double-blind trial of valaciclovir prophylaxis for cytomegalovirus disease in patients with advanced human immunodeficiency virus infection. AIDS Clinical Trials Group Protocol 204/Glaxo Wellcome 123–014 International CMV Prophylaxis Study Group J Infect Dis 1998 177: 48–56

    Article  CAS  PubMed  Google Scholar 

  20. Landry ML, Ferguson D, Stevens-Ayers T et al. Evaluation of CMV Brite kit for detection of cytomegalovirus pp65 antigenemia in peripheral blood leukocytes by immunofluorescence J Clin Microbiol 1996 34: 1337–1339

    CAS  PubMed  PubMed Central  Google Scholar 

  21. Salzberger B, Bowden RA, Hackman RC et al. Neutropenia in allogeneic marrow transplant recipients receiving ganciclovir for prevention of cytomegalovirus disease: risk factors and outcome Blood 1997 90: 2502–2508

    CAS  PubMed  Google Scholar 

  22. Boeckh M, Gooley TA, Myerson D et al. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovirversus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study Blood 1996 88: 4063–4071

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology and Oncology, Department of Medicine, Vanderbilt University School of Medicine and VA Medical Center, Nashville, TN, USA

    M Vusirikala, SN Wolff, RS Stein, SJ Brandt, DS Morgan, JP Greer, FG Schuening & SA Goodman

  2. Department of Medicine, and the Division of Infectious Diseases, Department of Medicine, Vanderbilt University School of Medicine and VA Medical Center, Nashville, TN, USA

    JS Dummer

Authors
  1. M Vusirikala
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. SN Wolff
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. RS Stein
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. SJ Brandt
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. DS Morgan
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. JP Greer
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. FG Schuening
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. JS Dummer
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. SA Goodman
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Vusirikala, M., Wolff, S., Stein, R. et al. Valacyclovir for the prevention of cytomegalovirus infection after allogeneic stem cell transplantation: a single institution retrospective cohort analysis. Bone Marrow Transplant 28, 265–270 (2001). https://doi.org/10.1038/sj.bmt.1703129

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1703129

Keywords

This article is cited by

Search

Advanced search

Quick links